|
Cytochrome-c Oxidase Deficiency
|
0.350 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutation in mitochondrial complex IV subunit COX5A causes pulmonary arterial hypertension, lactic acidemia, and failure to thrive.
|
28247525 |
2017 |
|
Cytochrome-c Oxidase Deficiency
|
0.350 |
Biomarker
|
disease |
BEFREE |
The Leigh syndrome of SLSJ-COX differs from that of SURF1-related COX deficiency.
|
21266382 |
2011 |
|
Cytochrome-c Oxidase Deficiency
|
0.350 |
Biomarker
|
disease |
BEFREE |
The accumulation of H(2)S over time causes progressive COX deficiency in animal tissues and human cells, which is associated with reduced amount of COX holoenzyme, and of several COX subunits, including mitochondrially encoded cytochrome c oxidase 1 (MTCO1), MTCO2, COX4, and COX5A.
|
20812865 |
2011 |
|
Cytochrome-c Oxidase Deficiency
|
0.350 |
Biomarker
|
disease |
BEFREE |
Nuclear-encoded COX genes should be reconsidered and included in the diagnostic mutational screening of human disorders related to COX deficiency.
|
18499082 |
2008 |
|
Cytochrome-c Oxidase Deficiency
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Our report of two patients with isolated COX deficiency and new mutations in COX subunit genes may help to draw more attention to this type of mtDNA defects and provide new aspects for counselling affected families.
|
16288875 |
2005 |
|
Cytochrome-c Oxidase Deficiency
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
No mitochondrial cytochrome oxidase (COX) gene mutations in 18 cases of COX deficiency.
|
9402980 |
1997 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the use of COX inhibitors was associated with a reduced risk of HCC in CHB.
|
31505085 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
COX regression analysis showed that FEAT was an independent prognostic factor for recurrence in breast cancer, but not for survival.
|
27881013 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their anti-inflammatory, analgesic, and antipyretic effects by reversibly or irreversibly acetylating COX isoforms, inhibiting downstream prostaglandins, and may have a chemopreventive role in malignancies, including skin cancer.
|
30523664 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The COX proportional hazard model predicts that among these, the relative expression of circRNA_104916 and lymphatic metastatic status independently predict the prognosis of patients with cancer.
|
30844715 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Apart from their anti-inflammatory action, COX inhibitors have gathered the interest of many scientists due to their potential use for the treatment and prevention of cancer.
|
31064095 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the survival analysis, COX regression showed that T stage, plasma miRNA 106b and tumor miRNA 93 were significant risk factors for overall survival [HR: 0.400 (0.205-0.780); <i>P </i>= 0.007; HR: 0.371 (0.142-0.969), <i>P </i>= 0.043; 0.295 (0.134-0.650), <i>P </i>= 0.002].
|
31384175 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Many in vitro and in vivo studies on human and animal models have explained the mechanisms of the chemopreventive effect of COX inhibitors such as: induction of apoptosis, inhibition of neoplasia, angiogenesis suppression, induction of cell cycle inhibition and inhibition of the expression of peroxisome proliferator-activated receptors.
|
30897717 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequently, univariate COX analysis identified that high expression of SOX8 (P = .004), differentiation (P = .006), distant metastasis (P <.001), tumor stage (P = .003), and higher rate of lymph node metastasis (P <.001), all significantly predicted decrease in OS.
|
31277140 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
COX regression analysis showed that FEAT was an independent prognostic factor for recurrence in breast cancer, but not for survival.
|
27881013 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Apart from their anti-inflammatory action, COX inhibitors have gathered the interest of many scientists due to their potential use for the treatment and prevention of cancer.
|
31064095 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The COX proportional hazard model predicts that among these, the relative expression of circRNA_104916 and lymphatic metastatic status independently predict the prognosis of patients with cancer.
|
30844715 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate COX regression analysis was performed to screen the candidate genes significantly associated with OS of HCC in a discovery cohort (GSE14520) for the least absolute shrinkage and selection operator modelling.
|
31011256 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate COX regression analysis was performed to screen the lncRNAs significantly associated with recurrence-free survival (RFS) of HCC in GSE76427 for the least absolute shrinkage and selection operator (LASSO) modelling.
|
30670911 |
2019 |
|
Alcohol consumption
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries.
|
29912962 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The risk factors for the prognosis of patients with different subtypes of BC were analyzed using Kaplan‑Meier and COX regression analyses.
|
29620140 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The SNPs in the COX genes may help us to evaluate the cancer risk of HCC.
|
28703354 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
[(Prop-2-ynyl)-2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS), an organometallic derivative of the irreversible cyclooxygenase-1/2 (COX-1/2) inhibitor acetylsalicylic acid (ASS), demonstrated high growth-inhibitory potential against various tumor cell lines and inhibition of both COX isoenzymes.
|
29492489 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
COX regression multivariate analysis identified post auto-SCT treatment failure before 12 months (hazard ratio (HR) 3.37, CI 1.7-6.6, P value < 0.001), presence of B symptoms (HR 2.55, CI 1.4-4.6, P value 0.002), stages III-IV (HR 2.7, CI 1.5-4.9, P value 0.001), albumin < 4 g/dl (HR 1.76, CI 1.1-2.9, P value 0.027) and tumor > 5 cm (HR 1.1.9, CI 1.13-3.25, P value 0.015) as significant risk factors; P value < 0.001.
|
29484455 |
2018 |
|
Carcinogenesis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
These results demonstrated that <i>COX-2</i> promoter methylation was significantly higher in tumor tissues, and was an early event for GC, thus, <i>COX-2</i> gene methylation may be important in the initial development of gastric carcinogenesis.
|
30079321 |
2018 |